Gene Security Network (GSN), a developer of bioinformatics technology, has finished $20m financing round.

As part of the financing, the company has also changed its name to Natera.

Natera will use the proceeds to support the continued development and commercialization of the company’s non-invasive prenatal diagnostic test for Down syndrome and other genetic conditions.

Natera CEO Matthew Rabinowitz said they will continue to develop diagnostics that lead the industry in terms of the breadth, speed and reliability of information delivered to expecting couples at the early stages of pregnancy.

The financing round was led by Lightspeed Venture Partners, which is joined in the current round by Claremont Creek Ventures and Sequoia Capital.